AR072396A1 - Proceso para preparar derivados de pirimidina sustituidos - Google Patents
Proceso para preparar derivados de pirimidina sustituidosInfo
- Publication number
- AR072396A1 AR072396A1 ARP090102405A AR072396A1 AR 072396 A1 AR072396 A1 AR 072396A1 AR P090102405 A ARP090102405 A AR P090102405A AR 072396 A1 AR072396 A1 AR 072396A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- formula
- compound
- hydrogen
- alkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
- C07C211/20—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic unsaturated carbon skeleton
- C07C211/22—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic unsaturated carbon skeleton containing at least two amino groups bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
- C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente se refiere a procesos para preparar derivados de pirimidina sustituidos, utiles como intermediarios en la síntesis de los moduladores de los receptores de histamina H4, y a intermediarios en la síntesis de los moduladores de H4. Reivindicacion 1: Un proceso para preparar un compuesto de formula (1) en donde L1 es CN; Rc se selecciona del grupo formado por H, metilo, etilo, propilo, isopropilo, -CF3, ciclopropilo, y ciclobutilo; R6 es hidrogeno; R8 se selecciona del grupo formado por hidrogeno y alquilo C1-4; Z se selecciona del grupo formado por N y CH; n es 1 o 2; R9, R10 y R11 se seleccionan cada uno de manera independiente del grupo formado por hidrogeno y alquilo C1-4; y sus sales aceptables para el uso farmacéutico; que comprende hacer reaccionar un compuesto de formula (2) en donde PG1 y PG2 son cada uno de manera independiente un grupo protector de nitrogeno, con un compuesto de formula (3), en donde LG1 es un grupo saliente, en un primer solvente orgánico; y cuando LG1 es -OH, en presencia de un sistema de agentes de acoplamiento; para obtener el correspondiente compuesto de formula (4); desproteger el compuesto de formula (4), para obtener el correspondiente compuesto de formula (5); y hacer reaccionar el compuesto de formula (5) con un compuesto de formula (6), en un segundo solvente orgánico, para obtener el correspondiente compuesto de formula (1), en donde X se selecciona del grupo formado por -N(R20)2 y -OR21; en donde cada R20 se selecciona de manera independiente del grupo formado por alquilo C1-4 alternativamente los dos grupos R20 se toman juntos con el átomo de nitrogeno al cual están unidos para formar una estructura de anillos saturados seleccionada del grupo formado por piperidinilo, pirrolidinilo y morfolinilo; y en donde R21 se selecciona del grupo formado por alquilo C1-4 y bencilo. Reivindicacion 36: Un compuesto de formula (7) en donde PG3 es un grupo protector de nitrogeno; Rc se selecciona del grupo formado por H, metilo, etilo, propilo, isopropilo, -CF3, ciclopropilo, y ciclobutilo; o una de sus sales aceptables para el uso farmacéutico. Reivindicacion 39: Un compuesto de formula (8) en donde cada R0 es hidrogeno o un grupo protector de nitrogeno; y en donde los dos grupos R0 son iguales; R8 se selecciona del grupo formado por hidrogeno y alquilo C1-4; Z se selecciona del grupo formado por N y CH; n es 1 o 2; R9, R10 y R11 se seleccionan cada uno de manera independiente del grupo formado por hidrogeno y alquilo C1-4; con la condicion de que cuando R8 es hidrogeno, R9 es hidrogeno, R10 es hidrogeno, Z es N, n es 1 y R11 es metilo, entonces R0 es un grupo protector de nitrogeno, en donde el grupo protector de nitrogeno no es -C(O)OCH3; o su sal aceptable para el uso farmacéutico.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7675208P | 2008-06-30 | 2008-06-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR072396A1 true AR072396A1 (es) | 2010-08-25 |
Family
ID=41464882
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090102405 AR072396A1 (es) | 2008-06-30 | 2009-06-29 | Proceso para preparar derivados de pirimidina sustituidos |
Country Status (36)
| Country | Link |
|---|---|
| US (6) | US8309720B2 (es) |
| EP (5) | EP2924035A1 (es) |
| JP (1) | JP5416768B2 (es) |
| KR (1) | KR101675354B1 (es) |
| CN (1) | CN102137672B (es) |
| AR (1) | AR072396A1 (es) |
| AU (1) | AU2009267156B2 (es) |
| BR (1) | BRPI0913644A2 (es) |
| CA (1) | CA2729733C (es) |
| CO (1) | CO6341560A2 (es) |
| CY (1) | CY1116134T1 (es) |
| DK (1) | DK2310012T3 (es) |
| EA (1) | EA019361B1 (es) |
| EC (1) | ECSP11010745A (es) |
| ES (1) | ES2538135T3 (es) |
| HK (4) | HK1156857A1 (es) |
| HR (1) | HRP20150576T1 (es) |
| HU (1) | HUE024949T2 (es) |
| IL (4) | IL210214A (es) |
| JO (1) | JO3043B1 (es) |
| ME (1) | ME02154B (es) |
| MX (1) | MX2011000080A (es) |
| MY (1) | MY150601A (es) |
| NI (1) | NI201000232A (es) |
| NZ (1) | NZ590170A (es) |
| PE (1) | PE20110163A1 (es) |
| PL (1) | PL2310012T3 (es) |
| PT (1) | PT2310012E (es) |
| RS (1) | RS53985B1 (es) |
| SI (1) | SI2310012T1 (es) |
| SV (1) | SV2011003788A (es) |
| TW (3) | TWI498326B (es) |
| UA (1) | UA106724C2 (es) |
| UY (1) | UY31949A (es) |
| WO (1) | WO2010002774A1 (es) |
| ZA (1) | ZA201100759B (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2008012655A (es) | 2006-03-31 | 2008-12-16 | Janssen Pharmaceutica Nv | Benzoimidazol-2-il-pirimidinas y -pirazinas como moduladores de receptor de histamina h4. |
| US9371311B2 (en) | 2008-06-30 | 2016-06-21 | Janssen Pharmaceutica Nv | Benzoimidazol-2-yl pyrimidine derivatives |
| CN102137672B (zh) | 2008-06-30 | 2014-03-26 | 詹森药业有限公司 | 取代的嘧啶衍生物的制备方法 |
| JP5574294B2 (ja) * | 2010-11-04 | 2014-08-20 | 独立行政法人科学技術振興機構 | 光磁気記録媒体及び光磁気記録方法 |
| EP2964229B1 (en) | 2013-03-06 | 2019-12-11 | Janssen Pharmaceutica NV | Benzoimidazol-2-yl pyrimidine modulators of the histamine h4 receptor |
| CN106132926B (zh) * | 2014-03-28 | 2019-05-21 | 株式会社钟化 | 三苄氧羰基精氨酸的制造方法 |
| BR112019008824A2 (pt) | 2016-11-03 | 2019-07-09 | Bristol-Myers Squibb Company | derivados heterocíclicos bicíclicos substituídos úteis como inibidores de canal de romk |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3005852A (en) | 1959-12-22 | 1961-10-24 | Gen Aniline & Film Corp | Production of sulfoxides and sulfones |
| US3931195A (en) * | 1971-03-03 | 1976-01-06 | Mead Johnson & Company | Substituted piperidines |
| US4191828A (en) * | 1976-04-14 | 1980-03-04 | Richardson-Merrell Inc. | Process for preparing 2-(2,2-dicyclohexylethyl)piperidine |
| US4190601A (en) * | 1978-05-31 | 1980-02-26 | Union Carbide Corporation | Production of tertiary amines by reductive alkylation |
| JPS5942396A (ja) * | 1982-09-02 | 1984-03-08 | Ishihara Sangyo Kaisha Ltd | リン酸アミド誘導体およびそれらを含有する殺虫、殺ダニ、殺線虫剤 |
| JPS6130576A (ja) | 1984-07-24 | 1986-02-12 | Ube Ind Ltd | ２−アミノ−５−シアノピリミジンの製法 |
| WO1994008577A1 (en) * | 1992-10-14 | 1994-04-28 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
| GB9422391D0 (en) | 1994-11-05 | 1995-01-04 | Solvay Interox Ltd | Oxidation of organosulphur compounds |
| IL137922A0 (en) * | 1998-02-17 | 2001-10-31 | Tularik Inc | Anti-viral pyrimidine derivatives |
| GB9914258D0 (en) * | 1999-06-18 | 1999-08-18 | Celltech Therapeutics Ltd | Chemical compounds |
| AU7738100A (en) * | 1999-09-30 | 2001-04-30 | Neurogen Corporation | Certain alkylene diamine-substituted pyrazolo(1,5,-a)-1,5-pyrimidines and pyrazolo(1,5-a)-1,3,5-triazines |
| US6693194B2 (en) | 2000-07-21 | 2004-02-17 | Syngenta Crop Protection, Inc. | Process for the preparation of 4,6-dimethoxy-2-(methylsulfonyl)-1,3-pyrimidine |
| PE20020506A1 (es) * | 2000-08-22 | 2002-07-09 | Glaxo Group Ltd | Derivados de pirazol fusionados como inhibidores de la proteina cinasa |
| WO2002064096A2 (en) | 2001-02-16 | 2002-08-22 | Tularik Inc. | Methods of using pyrimidine-based antiviral agents |
| WO2002078701A1 (en) * | 2001-03-30 | 2002-10-10 | Smithkline Beecham Corporation | Use of pyrazolopyridines as therapeutic compounds |
| ES2262899T3 (es) * | 2001-12-17 | 2006-12-01 | Smithkline Beecham Corporation | Derivados de pirazolopiridazina. |
| TWI270542B (en) | 2002-02-07 | 2007-01-11 | Sumitomo Chemical Co | Method for preparing sulfone or sulfoxide compound |
| DE60329030D1 (de) * | 2002-12-04 | 2009-10-08 | Ore Pharmaceuticals Inc | Melanocortin-rezeptormodulatoren |
| JP2006525261A (ja) * | 2003-05-05 | 2006-11-09 | エフ．ホフマン−ラ ロシュ アーゲー | Ｃｒｆ活性を有する縮合ピリミジン誘導体 |
| EP1809745A2 (en) | 2004-10-27 | 2007-07-25 | Schering Corporation | COMPOSITIONS AND METHODS FOR SHORT INTERFERING NUCLEIC ACID INHIBITION OF NAv1.8 |
| EA015890B1 (ru) | 2005-06-14 | 2011-12-30 | Тайджен Байотекнолоджи Ко. Лтд. | Производные пиримидина |
| CN101218023B (zh) * | 2005-07-06 | 2012-02-08 | 通用电气健康护理生物科学股份公司 | 制备分离基质的方法 |
| TW200800201A (en) * | 2005-11-18 | 2008-01-01 | Lilly Co Eli | Pyrimidinyl benzothiophene compounds |
| CN101032483B (zh) * | 2006-03-09 | 2011-05-04 | 陈德桂 | 调节雄激素受体活性的乙内酰脲衍生物及其应用 |
| DE602007008859D1 (de) * | 2006-03-31 | 2010-10-14 | Janssen Pharmaceutica Nv | Benzoimidazol-2-yl pyridine als modulatoren des histamin-h4-rezeptors |
| MX2008012655A (es) * | 2006-03-31 | 2008-12-16 | Janssen Pharmaceutica Nv | Benzoimidazol-2-il-pirimidinas y -pirazinas como moduladores de receptor de histamina h4. |
| CN102137672B (zh) | 2008-06-30 | 2014-03-26 | 詹森药业有限公司 | 取代的嘧啶衍生物的制备方法 |
| SG192446A1 (en) * | 2008-06-30 | 2013-08-30 | Janssen Pharmaceutica Nv | Process for the preparation of benzoimidazol-2-yl pyrimidine derivatives |
-
2009
- 2009-06-29 CN CN200980134933.7A patent/CN102137672B/zh not_active Expired - Fee Related
- 2009-06-29 AR ARP090102405 patent/AR072396A1/es not_active Application Discontinuation
- 2009-06-29 MY MYPI2010006258A patent/MY150601A/en unknown
- 2009-06-29 TW TW098121755A patent/TWI498326B/zh not_active IP Right Cessation
- 2009-06-29 RS RS20150287A patent/RS53985B1/en unknown
- 2009-06-29 PE PE2010001216A patent/PE20110163A1/es not_active Application Discontinuation
- 2009-06-29 EP EP15157445.6A patent/EP2924035A1/en not_active Withdrawn
- 2009-06-29 EA EA201170113A patent/EA019361B1/ru not_active IP Right Cessation
- 2009-06-29 WO PCT/US2009/049027 patent/WO2010002774A1/en active Application Filing
- 2009-06-29 EP EP20140161564 patent/EP2769721A3/en not_active Withdrawn
- 2009-06-29 EP EP15157453.0A patent/EP2924023A1/en not_active Withdrawn
- 2009-06-29 JP JP2011516757A patent/JP5416768B2/ja not_active Expired - Fee Related
- 2009-06-29 EP EP20090774225 patent/EP2310012B1/en active Active
- 2009-06-29 ME MEP-2015-79A patent/ME02154B/me unknown
- 2009-06-29 JO JOP/2009/0240A patent/JO3043B1/ar active
- 2009-06-29 SI SI200931188T patent/SI2310012T1/sl unknown
- 2009-06-29 US US12/459,229 patent/US8309720B2/en active Active
- 2009-06-29 HU HUE09774225A patent/HUE024949T2/en unknown
- 2009-06-29 KR KR1020117001991A patent/KR101675354B1/ko active IP Right Grant
- 2009-06-29 CA CA2729733A patent/CA2729733C/en not_active Expired - Fee Related
- 2009-06-29 TW TW103118001A patent/TW201433568A/zh unknown
- 2009-06-29 MX MX2011000080A patent/MX2011000080A/es active IP Right Grant
- 2009-06-29 AU AU2009267156A patent/AU2009267156B2/en not_active Ceased
- 2009-06-29 PT PT97742258T patent/PT2310012E/pt unknown
- 2009-06-29 ES ES09774225.8T patent/ES2538135T3/es active Active
- 2009-06-29 TW TW103104509A patent/TWI481603B/zh not_active IP Right Cessation
- 2009-06-29 DK DK09774225T patent/DK2310012T3/da active
- 2009-06-29 BR BRPI0913644A patent/BRPI0913644A2/pt not_active Application Discontinuation
- 2009-06-29 EP EP15157463.9A patent/EP2924025A1/en not_active Withdrawn
- 2009-06-29 NZ NZ590170A patent/NZ590170A/en not_active IP Right Cessation
- 2009-06-29 UA UAA201100983A patent/UA106724C2/uk unknown
- 2009-06-29 PL PL09774225T patent/PL2310012T3/pl unknown
- 2009-06-30 UY UY31949A patent/UY31949A/es unknown
-
2010
- 2010-12-23 IL IL210214A patent/IL210214A/en active IP Right Grant
- 2010-12-23 NI NI201000232A patent/NI201000232A/es unknown
-
2011
- 2011-01-03 SV SV2011003788A patent/SV2011003788A/es unknown
- 2011-01-04 CO CO11000461A patent/CO6341560A2/es not_active Application Discontinuation
- 2011-01-05 EC ECSP11010745 patent/ECSP11010745A/es unknown
- 2011-01-28 ZA ZA2011/00759A patent/ZA201100759B/en unknown
- 2011-10-19 HK HK11111216.2A patent/HK1156857A1/xx not_active IP Right Cessation
-
2012
- 2012-10-29 US US13/663,233 patent/US9079882B2/en not_active Expired - Fee Related
-
2013
- 2013-03-15 US US13/844,227 patent/US9079883B2/en not_active Expired - Fee Related
- 2013-11-11 US US14/076,955 patent/US9079884B2/en not_active Expired - Fee Related
- 2013-11-12 US US14/078,153 patent/US9006432B2/en not_active Expired - Fee Related
- 2013-11-13 US US14/079,358 patent/US9359327B2/en not_active Expired - Fee Related
-
2014
- 2014-11-09 IL IL235572A patent/IL235572A/en active IP Right Grant
- 2014-11-09 IL IL235571A patent/IL235571A/en active IP Right Grant
- 2014-11-09 IL IL235570A patent/IL235570A/en active IP Right Grant
-
2015
- 2015-02-26 HK HK15101911.7A patent/HK1201441A1/xx unknown
- 2015-03-23 CY CY20151100293T patent/CY1116134T1/el unknown
- 2015-05-29 HR HRP20150576TT patent/HRP20150576T1/hr unknown
-
2016
- 2016-03-03 HK HK16102449.5A patent/HK1214590A1/zh unknown
- 2016-03-23 HK HK16103405.5A patent/HK1215434A1/zh unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR072396A1 (es) | Proceso para preparar derivados de pirimidina sustituidos | |
| ES2254047T1 (es) | Procedimiento de preparacion de derivados de topiramato anticonvulsivos. | |
| ES2422204T3 (es) | Novedosos derivados de imidazolidin-2-ona como moduladores selectivos de receptor de andrógenos (SARMS) | |
| AR066659A1 (es) | Derivados de espiroindolinona | |
| HRP20211072T1 (hr) | Sinteza indazola | |
| AR090203A1 (es) | Compuestos heterobiciclicos como inhibidores de pde10 | |
| CO5580815A2 (es) | Derivados de adamantana, procesos para su preparacion y composiciones farmaceuticas que los contienen | |
| AR053120A1 (es) | Aminopiridinas como inhibidores de beta secretasa | |
| DOP2010000046A (es) | Compuestos de biciclolactama sustituida | |
| AR077695A1 (es) | Derivados de pirimidina como inhibidores del factor ixa | |
| AR066562A1 (es) | Derivados de pirrol condensados; una formulacion farmaceutica en base al compuesto y su uso para preparar medicamentos | |
| AR063912A1 (es) | Derivados de 1,2,4 oxadiazol. composiciones farmaceuticas. | |
| PE20130375A1 (es) | Compuestos de triazolopiridinas y triazolopirazinas inhibidores de c-met y composiciones de los mismos | |
| AR072906A1 (es) | Nucleosidos modificados utiles como antivirales | |
| AR082499A1 (es) | Compuestos utiles para trastornos del sistema nervioso, inflamatorios, estomacales y como analgesicos | |
| PE20110417A1 (es) | Proceso para la preparacion de derivados de l-alanina protegidos | |
| CO6300864A2 (es) | Derivados polisustituidos de 6-heteroaril-imidazo[1,2-a]piridinas su preparacion y su aplicacion en terapeutica | |
| AR079226A1 (es) | Espiroindolinona- pirrolidinas, procesos de preparacion y uso de los mismos para el tratamiento y profilaxis del cancer | |
| AR068538A1 (es) | Compuesto heterociclico de 5 miembros con actividad supresora de la secrecion de acido | |
| DOP2010000022A (es) | Derivados de pirimidina 934 | |
| AR073003A1 (es) | Proceso para preparar 5-azacitosina nucleosidos y sus derivados | |
| AR059328A1 (es) | Derivados de antranilamida-2-amino-heteroareno-carboxamida, un proceso para su obtencion, composiciones farmaceuticas que los contienen y el uso de estos compuestos para la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por cetp | |
| AR081725A1 (es) | Derivados de oxadiazol, proceso de preparacion de los mismos, composicion farmaceutica que los contienen y su uso en el tratamiento del cancer | |
| PE20212327A1 (es) | Ciertos compuestos de pladienolida y metodos de uso | |
| AR091075A1 (es) | Proceso para preparar derivados monociclicos de heteroaril-cicloalquil-diamina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |